Skip to main content
Molecular Devices, LLC
  •   美谷分子仪器(上海)有限公司
    咨询服务热线:400-821-3787
  •  Careers
  •   Store
  •  Language  
    • English
    • Deutsch
    • 中文
    • 日本語
    • Français
    • 한국어
    • Italiano
    • Español
Molecular Devices, LLC
  • Products
    • Products

      Optimize your research timelines with the all NEW CloneSelect Imager FL

      • High-speed multichannel fluorescent imaging
      • Calculate cell growth with intelligent data analysis
      • Monoclonality report generation

      Learn more

      Cloneselect Imager FL

      Make your first move with confidence with the NEW SpectraMax® Mini Multi-Mode Microplate Reader

      It's as easy as 1-2-3

      • Set up
      • Analyze data
      • Get results

      Learn more

      SpectraMax Mini Multi-Mode Microplate Reader
    • Microplate Readers
      SpectraMax Mini Multi-Mode Microplate Reader
      Multi-Mode Readers
      • SpectraMax i3x
      • SpectraMax iD3/iD5
      • SpectraMax M Series
      • FlexStation 3
      • SpectraMax Mini
      Spectramax ABS Microplate
      Absorbance Readers
      • SpectraMax ABS/ABS Plus
      • SpectraMax VersaMax
      • SpectraMax QuickDrop
      • CMax Plus
      Fluorescence Readers
      Fluorescence Readers
      • SpectraMax Gemini
      SpectraMax Luminescence
      Luminescence Readers
      • SpectraMax L

       

      MultiWash+ Microplate Washer
      Microplate Stacker & Washer
      • StakMax Microplate Handler
      • AquaMax Washer
      • MultiWash+ Microplate Washer
      • MultiWash–C 微孔板洗板机
      SoftMax Pro Data Acquisition
      MICROPLATE SOFTWARE
      • SoftMax Pro Software
      • SoftMax Pro GxP Software
      GxP Solutions
      GxP Compliance Solutions
      • SoftMax Pro GxP Software
      • Software Installation & Validation Services
      • IQ/OQ/PM Services
      • SpectraTest Validation Plates
      Lab Automation & Customization
      Lab Automation & Customization
      • Lab automation for high-throughput plate-based assays
    • Cellular Imaging Systems
      ImageXpress Pico Automated Cell Imaging System
      Automated Cell Imaging Systems
      • ImageXpress Pico
      • ImageXpress Nano
      High-Content Imaging
      High-Content Imaging
      • ImageXpress Confocal HT.ai
      • ImageXpress Micro Confocal
      • ImageXpress Micro 4
      Stratominer Analytics
      Acquisition & Analysis Software
      • IN Carta
      • StratoMineR
      • MetaXpress
      • CellReporterXpress
      • MetaMorph
      Lab Automation & Customization
      Lab Automation & Customization
      • Lab automation for high-throughput, high content screening (HCS)
      • BioAssemblyBot 400 Bioprinter Automated HCS Solution
    • Clone Screening
      Clone Pix Series
      Mammalian Colony Picking
      • ClonePix 2
      QPix Microbial Colony Pickers
      Microbial Colony Picking
      • QPix 420
      • QPix 450/460
      • QPix HT
      Cloneselect Imager FL
      Single-Cell Imaging
      • CloneSelect Imager
      • CloneSelect Imager FL
      Clone Select Single Cell Printer
      Single-cell Isolation
      • CloneSelect Single-Cell Printer
      CloneMedia and XP Media
      Culture media & Reagents
      Lab Automation
      Lab Automation & Customization
      • Lab automation for high-throughput clone screening
    • Flipr Penta
      Flipr Penta
      FLIPR Penta
      • FLIPR Penta High-Throughput Cellular Screening System
      Screenworks
      ANALYSIS SOFTWARE
      • ScreenWorks Software
      • Peak Pro 2 Software Module
      Flipr Assay Kit
      FLIPR Assay Kits
      • Calcium Assay Kits
      • Potassium Assay Kit
      • Membrane Potential Assay Kit
      • EarlyTox Cardiotoxicity Kit
    • Axon Patch-Clamp
      Transparent
      Amplifiers
      • Axopatch 200B Capacitor
      • MultiClamp 700B
      • Axoclamp 900A
      Transparent
      Digitizers
      • Axon Digidata 1550B Low
      Transparent
      Acquisition &
      Analysis Software
      • pCLAMP 11 Software Suite
    • Additional Products
      Threshold Immunoassay System
      Threshold Immunoassay System
      Geneppix Microarray Scanners
      Genepix Microarray Scanners
      Imagexpress Micro Xls
      Imagexpress Micro xls
      Certified Refurbished
      Certified Refurbished
      IDBs Solutions
      R&D Cloud Solutions By IDBS
    • Lab Automation
      Lab Automation & Customization
      Lab Automation & Customization
      High Content Screening HCS
      HIGH-THROUGHPUT, HIGH CONTENT SCREENING
      • BioAssemblyBot 400 Bioprinter Automated HCS Solution
      High Throughput Plate Based Assays
      High-throughput Plate-Based Assays
      High Throughput Clone Screening
      High-throughput Clone Screening
    • GXP COMPLIANCE SOLUTIONS
      GxP Softmax Pro GxP Software
      SOFTMAX PRO GXP SOFTWARE
      GxP Software Installation
      SOFTWARE INSTALLATION & VALIDATION SERVICES
      GxP Spectratest Validation Plates Recertification
      SPECTRATEST VALIDATION PLATES
      IQ OQ Services
      IQ/OQ/PM SERVICES
    • Assay Kits
      Cardiotox
      • EarlyTox Cardiotoxicity Kit
      Cell viability
      • EarlyTox Cell Integrity Kit
      • EarlyTox Cell viability Assay Kits
      dna quantitation
      • Spectramax Quant dsDNA Assay Kits
      Elisa, western blot
      • CatchPoint SimpleStep ELISA Kits
      • ScanLater Western Blot Assay Kit
      gpcr
      • FLIPR Calcium Assay Kits
      • Fura-2 QBT Calcium Kit
      • CatchPoint cAMP Fluorescent Assay Kit
      • CatchPoint cGMP Fluorescent Assay Kit
      Ion channel
      • FLIPR Potassium Assay Kit
      • FLIPR Membrane Potential Assay Kits
      IGG QUANTIFICATION ASSAY
      • ValitaTiter Assay
      Reporter Gene
      • Spectramax Glo Steady-Luc Reporter Assay Kit
      • Spectramax DuoLuc Reporter Assay Kit
      TRANSPORTERS
      • QBT Fatty Acid Uptake Assay Kit
      • Neurotransmitter Transporters Uptake Assay Kit
      Other
      • Contaminant Detection Assays
      • Enzyme - IMAP Assays
    • Accessories & Consumables
      Microplate Readers
      • 384 Well SBS
      • 384 Well High Sample Recovery Plate
      • Deep-well Plates
      • Low Profile Microplates
      • SpectraDrop Micro-volume Microplate
      • SpectraMax Injection cartridge with SmartInject Technology
      • SpectraMax MiniMax 300 Imaging Cytometer
      • Western Blot Cartridge
      • 96孔微孔板
      Clone Screening
      • Adjustable Petri Dish and Microplate Holder
      • Bioassay QTrays
      • Calibeads
      • Cap Mats and Lids
      • Chroma Filters
      • Cleaning and Sterilizing Solutions
      • CloneSelect Single-Cell Printer Cartridges
      • QPix Pins and Heads
      • QReps Replicator
      Axon Patch-Clamp
      • Soft Panel Amplifier Control
      Spectra Img
  • Applications
    • APPLICATIONS

      Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce

      Dec 06, 2022

      • First-of-its-kind technology from Cellesce creates consistent patient-derived organoids for large-scale drug screening
      • Acquisition strengthens Molecular Devices’ position as a 3D biology solutions innovator
      • Combined expertise will accelerate industry adoption of physiologically-relevant cell models for drug discovery

       

      Visit the OIC

      Read press release

      Cellsce
      Spectra for Application
    • SARS-CoV-2 (COVID-19)
      Covid-19
      COVID-19 Research Solution
      Covid-19
      COVID-19 Company Update
      Covid-19
      Vaccine Development Workflows
      Infectious Disease Research Application
      Vaccine Research Applications
    • Research Areas
      Transparent
      3D Cell Models
      Transparent
      Cancer Research Solutions
      Transparent
      Cell Line Development
      Transparent
      Drug Discovery and Development
      Transparent
      Food & Beverage
      Transparent
      Gene Editing (CRISPR/Cas9)
      Transparent
      Organoid Research
      Transparent
      Stem Cell Research
      Transparent
      Toxicology
    • Microplate Readers
      Transparent
      Cell Health
      Transparent
      Cellular Signaling
      Transparent
      ELISA
      Transparent
      Microbiology & Contaminants
      Transparent
      NUCLEIC ACID (DNA/RNA) DETECTION & ANALYSIS
      Transparent
      Protein Detection, Quantitation, Analysis
      Transparent
      Technology: Detection Modes
      • Absorbance
      • Fluorescence
      • Fluorescence Polarization
      • Luminescence
      • TRF, TR-FRET & HTRF
      • Western Blot
    • Cellular Imaging Systems
      Transparent
      Cell Counting
      • HEK293-GFP Cells
      • NIH3T3 Cells
      • THP-1 Cells
      • View more cell types
      Transparent
      Cell Imaging & Analysis
      • High-Content Screening with AgileOptix Technology
      Transparent
      Cell Migration Assays
      Transparent
      Cell Painting
      Transparent
      Live Cell Imaging
      Transparent
      Neurite Outgrowth
      Transparent
      Organoids
      • Brain Organoids
      • Intestinal Organoids
      • PDO (Tumoroids)
      • Lung Organoids
      Transparent
      Spheroids
    • Clone Screening
      Transparent
      Cell Line Development Workflow
      Transparent
      Monoclonal Antibodies (mAbs)
      • Hybridoma
      • Phage Display
      • Monoclonal Antibody Production
      Transparent
      Monoclonality
      Transparent
      Synthetic Biology
    • Flipr Penta
      Transparent
      GPCRs (G protein-coupled receptors)
      Transparent
      Ion Channels
      Transparent
      Cardiotoxicity
    • Axon Patch-Clamp
      Transparent
      Patch Clamp Electrophysiology
  • Resources
    • Resources
    • Resource Hub
      Menu Resource Icons/Application Notes
      Application Notes
      Menu Resource Icons/Citations
      Citations
      Ebook Icon
      eBooks
      Menu Resource Icons/Scientific Posters
      Scientific Posters
      Menu Resource Icons/Tutorial and Videos
      Videos & Webinars

      Search

    • Blog – Lab Notes
      Spacer
      Celebrating the art of…
      Spacer
      Advanced technology for…
      3D organoids and automation of complex cell assays [Podcast]
      Jan 27, 2023As we enter the era of sophisticated drug discovery with gene therapy and personalized medicine, we need to be prepared to study complex diseases, assess the therapeutic…
      Read more  
    • Customer Breakthroughs

      Learn how scientists are advancing discovery with our products and solutions.

    • Innovations
      Transparent
      AI, MACHINE LEARNING & DEEP LEARNING
      Transparent
      AgileOptix Spinning Disk Technology
      Transparent
      Autofocus
      Transparent
      Digital Confocal Option
      Transparent
      High Content Screening
      Transparent
      HumSilencer Technology
      Transparent
      Laser Illumination
      Transparent
      QuickID Targeted Image Acquisition
    • Technology
      Transparent
      Absorbance
      Transparent
      Electrophysiology
      Transparent
      Fluorescence
      Transparent
      Fluorescence Polarization (FP)
      Transparent
      Luminescence
      Transparent
      TRF, TR-FRET & HTRF
      Transparent
      Water Immersion Objectives
      Transparent
      Western Blot
    • Video Gallery
      Transparent
      Microplate Readers
      Transparent
      Cellular Imaging Systems
      Transparent
      Flipr System
      Transparent
      Clone Screening
      Transparent
      Axon Patch-Clamp
      Transparent
      On-Demand Webinar
  • Services & Support
    • Services & Support
    • Overview
      Spectra Logo
      SPECTRANET CUSTOMER CARE PORTAL
      Lab Automation & Customization
      LAB AUTOMATION & CUSTOMIZATION
      Professional Services
      PROFESSIONAL SERVICE
      Service Plans
      SERVICE PLANS
      GxP Compliance
      GXP COMPLIANCE SOLUTION
    • Spectranet - Customer Portal
      Spectranet

      INTRODUCING OUR NEW CUSTOMERCARE PORTAL

      SpectraNet is an intuitive, simple-to-use, self-service customer portal providing a new level of experience available 24/7.

      Create your account today to get full access to integrated content and world-class customer service.

      REGISTER LOGIN
      File Support Ticket
      File a support ticket
      Knowledge Base
      Knowledge base
      Register Product
      Register your product
      Technical Resource
      Technical resources
  • Company
    • Company

      MOLECULAR DEVICES EXPANDS GLOBAL R&D HUB IN AUSTRIA

      Oct 12, 2022        
      Larger site will be future home of the Organoid Innovation Center – Salzburg, a collaborative space for advancing automated cell line development, organoid development, and screening solutions to improve drug discovery

       

      Visit the OIC

      Read press release

      Ribbon Cutting Ceremony of Austrian Research & Development Center
      Spectra for Application
    • About Us

      Providing our customers with innovative bioanalytical solutions for protein and cell biology for over 30 years.

    • Leadership
      Molecular Devices Leadership
    • Careers

      Our team-oriented corporate culture ensures diversity of thought, perspective, and a strong relationship of trust.

    • Newsroom
      Transparent
      NEWS
      Transparent
      IN-THE-NEWS
      Molecular Devices and Advanced Solutions Life Sciences collaborate to develop 3D Biology Automation Technologies for Drug Discovery
      Jan 04, 2023 Turnkey platform integrates flexible robotic automation with high-content imaging of complex 3D cellular models, enabling high-volume organoid…
      Read more  
    • Events
      BPS (Biophysical Society)
      Conference | North America | San Diego, CA USA– Feb 18 – Feb 22, 2023 Booth 634 As science becomes increasingly interdisciplinary, the Biophysical Society Annual Meeting continues its long-held reputation for bringing…
      Read more  
      SLAS (Society for Laboratory Automation and Screening)
      Conference | North America | San Diego, CA USA– Feb 25 – Mar 1, 2023 Booth 917 The Society for Laboratory Automation and Screening (SLAS) is an international professional society of academic, industry and government…
      Read more  
  • Contact Us
  • Search

    Search

  • Request Quote

Mobile navigation

  • Products
    • All Products
    • Microplate readers
      • Multi-Mode Readers
      • Absorbance Readers
      • Fluorescence Readers
      • Luminescence Readers
      • Microplate Stacker
      • Microplate Washers
      • SoftMax Pro Software
      • SoftMax Pro GxP Software
      • GxP Compliance Solutions
      • Lab Automation & Customization
    • Cellular Imaging Systems
      • Automated Cell Imaging Systems
      • High-Content Imaging
      • Acquisition & Analysis Software
      • Lab Automation & Customization
    • Clone Screening
      • Mammalian Colony Picking
      • Microbial Colony Picking
      • Single-Cell Imaging
      • Single-cell Isolation
      • Culture Media & Reagents
      • Lab Automation & Customization
    • FLIPR Penta
      • FLIPR Penta
      • ANALYSIS SOFTWARE
      • FLIPR ASSAY KITS
    • Axon Patch-Clamp
      • Amplifiers
      • Digitizers
      • pCLAMP Software
    • Additional Products
      • Threshold Immunoassay System
      • GenePix Microarray Systems
      • ImageXpress Micro XLS
      • Certified Refurbished
      • R&D CLOUD SOLUTIONS BY IDBS
    • LAB AUTOMATION
      • Lab Automation & Customization
      • HIGH-THROUGHPUT, HIGH CONTENT SCREENING
      • High-throughput Plate-Based Assays
      • High-throughput Clone Screening
    • GXP COMPLIANCE SOLUTIONS
      • GXP SOFTWARE INSTALLATION AND VALIDATION
      • IQ/OQ/PM SERVICES
      • SOFTMAX PRO GXP SOFTWARE
      • SpectraTest Validation Plates and Recertification
    • Assay Kits
      • Cardiotox
      • CELL VIABILITY
      • DNA QUANTITATION
      • ELISA, WESTERN BLOT
      • GPCR
      • ION CHANNEL
      • REPORTER GENE
      • Transporters
      • OTHER
    • Accessories and Consumables
      • MICROPLATE READERS
      • CLONE SCREENING
      • Axon Patch-Clamp
  • Applications
    • All Applications
    • SARS-CoV-2 (COVID-19)
      • COVID-19 Research Solution
      • COVID-19 Company Update
      • Vaccine Development Workflows
      • Vaccine Research Applications
    • Research Areas
      • 3D Cell Models
      • Cancer Research Solutions
      • Cell Line Development
      • Drug Discovery and Development
      • Food & Beverage
      • Gene Editing (CRISPR/Cas9)
      • Organoid Innovation Center
      • Stem Cell Research
      • Toxicology
    • Microplate Readers
      • Cell Health
      • Cellular Signaling
      • ELISA
      • Microbiology & Contaminants
      • NUCLEIC ACID (DNA/RNA) DETECTION & ANALYSIS
      • PROTEIN DETECTION, QUANTITATION, ANALYSIS
      • Technology: Detection modes
        • Absorbance
        • Fluorescence
        • Fluorescence Polarization
        • Luminescence
        • TRF, TR-FRET & HTRF
        • Western Blot
    • Cellular Imaging Systems
      • Cell Counting
        • HEK293-GFP Cells
        • NIH3T3 Cells
        • THP-1 Cells
        • View more cell types
      • Cell Imaging & Analysis
        • High-Content Screening with AgileOptix Technology
      • Cell Migration Assays
      • Cell Painting
      • Live Cell Imaging
      • Neurite Outgrowth
      • Organoids
        • Brain Organoids
        • Intestinal Organoids
        • PDO (Tumoroids)
        • Lung Organoids
      • Spheroids
    • Clone Screening
      • Monoclonal Antibodies (mAbs)
      • Monoclonality
      • Synthetic Biology
    • Flipr Penta
      • GPCRs (G protein-coupled receptors)
      • Ion Channels
      • Cardiotoxicity
    • Axon Patch-Clamp
      • Patch Clamp Electrophysiology
  • Resources
    • Resource Hub
      • Application Notes
      • Citations
      • eBooks
      • Scientific Posters
      • Videos & Webinars
    • Blog–Lab Notes
    • Customer Breakthroughs
    • Innovations
      • AI, MACHINE LEARNING & DEEP LEARNING
      • AgileOptix Spinning Disk Technology
      • Autofocus
      • Digital Confocal Option
      • High Content Screening
      • HumSilencer Technology
      • Laser Illumination
      • QuickID Targeted Image Acquisition
    • Technology
      • Absorbance
      • Electrophysiology
      • Fluorescence
      • Fluorescence Polarization (FP)
      • Luminescence
      • TRF, TR-FRET & HTRF
      • Water Immersion Objectives
      • Western Blot
    • Video Gallery
      • Microplate Readers
      • Cellular Imaging Systems
      • Flipr System
      • Clone Screening
      • Axon Patch-Clamp
      • On-Demand Webinar
  • Services & Support
    • Overview
      • SPECTRANET Customer Care Portal
      • LABORATORY AUTOMATION SOLUTIONS
      • PROFESSIONAL SERVICE
      • SERVICE PLANS
      • GXP COMPLIANCE SOLUTION
    • Spectranet - Customer Portal
      • REGISTER
      • LOGIN
      • File a support ticket
      • Knowledge base
      • Register your product
      • Technical resources
  • Company
    • About Us
    • Leadership
    • Careers
    • Newsroom
      • News
      • In The News
    • Events
  • Contact Us
  • Request Quote
  1. Home
  2. Lab Notes
  3. Clone Screening
  4. The role of Monoclonal Antibodies against COVID-19
Molecular Devices Lab Notes

The role of Monoclonal Antibodies against COVID-19

  • April 14, 2022
  • Guest Bloggers: Carter Mitchell and Sharath Madasu

Discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their discovery and development pipeline.

Over the past three years, the development of treatments for COVID-19 gained substantial momentum. Vaccination has been at the forefront of the battle. Through mRNA administration, vaccines prompt your cells to produce a harmless version of the spike protein, thereby stimulating your immune system to produce antibodies to fight off the potential threat. The question is, what happens when you have already contracted COVID-19, or your immune system is compromised such that you are at high risk of hospitalization even after vaccination. That is where monoclonal antibodies step in by targeting and neutralizing the virus after it invades the body.

 

Featured podcast

On the newest podcast with Drug Target Review (Episode 6 - mAbs and SARS-CoV-2 with Dr. Carter Mitchell & Dr. Sharath Madasu, Kemp Proteins), Carter Mitchell, Chief Scientific Officer and Sharath Madasu, Manager of Protein Characterization of Kemp Proteins, discussed the role of monoclonal antibodies (mAbs) against COVID-19 and how the pandemic has shaped their discovery and development.

 

Drug Target Review · Episode 6 - mAbs and SARS-CoV-2 with Dr Carter Mitchell & Dr Sharath Madasu, Kemp Proteins

Table of contents

  • Why are mAbs effective against SARS-CoV-2?
  • Advantages of mAbs over other Covid-19 therapies
  • The effect of a sudden pandemic
  • COVID-19 monoclonal antibody workflow
  • Challenges and bottlenecks

  • Time and financial constraints
  • Ensuring monoclonality and accelerating COVID-19 mAb production with automation
  • Automation of mAb lab processes in the future
  • Future of SARS-CoV-2 research and the role of monoclonal antibodies
  • Monoclonal antibody discovery for COVID-19 with Molecular Devices’ lab automation solutions
     

 

Why are mAbs effective against SARS-CoV-2?

Monoclonal antibodies (mAbs) act on viruses through viral neutralization. They are effective because they interrupt the process by which the virus either recognizes the host or the virus is internalized.

 

Working mechanism of monoclonal antibodies

In SARS-CoV-2, the aim is to disrupt the binding of the spike protein with ACE2 receptors, prohibiting the entry of the virus into the host cells. The spike protein mediates the binding through its recognition binding domain (RBD). Currently, most of the neutralizing monoclonal antibodies are raised against the RBD.

 

How effective are monoclonal antibodies against COVID-19 variants?

When it comes to effectiveness, it is difficult to give a single answer because of the growing number of variants. Efficacy varies across the variants. For instance, although most Emergency Use Authorized antibodies work on the Alpha and the Delta Variants, they exhibit a lower efficacy in the Omicron Variant.

The challenge with Omicron is that there are at least 36 mutations on the spike protein, some of which are located on the RBD. These mutations result in differential glycosylation, allowing the virus to evade previously-formed immunologic responses or monoclonal antibody neutralization.

Fortunately, newer antibodies, such as Sotrovimab, managed to retain their neutralizing activity in the recent variants, so there is still a glimmer of hope. Nevertheless, efficacy may highly vary. Some antibodies are very effective against Alpha and Beta Variants but not against the Gamma or Delta variants. In contrast, the antibodies effective against Delta and Alpha are much less effective against the Beta, Gamma and Omicron variants.

The impact of a particular variant mutation on EC50 depends on whether the mutations are at the binding epitope or not.

 

Advantages of mAbs over other Covid-19 therapies

The level of certainty in the required dosage is one of the main advantages of monoclonal antibodies in COVID-19 treatment.

According to Dr. Madasu, the success rate of convalescent plasma therapy relies heavily on the donor. Madasu further explains: “With the convalescent plasma therapy, A) you are expecting that the donor is still producing neutralizing antibodies, and B) Donor is producing sufficient amounts to be effective at all. With monoclonal antibodies, we know exactly how much of a neutralizing antibody we are administering to the patient, which is a huge advantage.”

Convalescent plasma therapy also brings about a substantial risk of plasma incompatibilities between patients. The use of monoclonal antibodies as an effective COVID-19 treatment method reduces these risks significantly.

Dr. Mitchell emphasizes another noteworthy feature of mAb therapy, the ability to produce a subset of pseudo polyclonal mixture that can neutralize any sort of variant that might emerge in the future. One might ask: How could we be so certain that these antibodies will be effective against future variants? Since each subset has a specific binding epitope, the mutations can quickly be recognized by one or a combination of mAb subsets.

Dr. Mitchell gives a plausible example of the potential benefits of polyclonal mixtures. “Five years from now, if a new type of variant comes out, we might be able to use a monoclonal antibody raised against the wild type PLUS one that came out in 2023 as a combination therapy to have more efficacy against that particular variant.”

The effect of a sudden pandemic

Monoclonal antibody development has undeniably been moving forward. The question remains: would the advancements in monoclonal antibody production still have taken place had it not been for the COVID-19 pandemic?

Although the process for monoclonal antibody development had already been established, the pandemic created a sense of urgency. Dr. Madasu also believes that people have an easier/better understanding of antibody therapies than that of vaccines. During the early phase of the pandemic, it was not clear how effective a vaccine would be, so certain sections of people may have hesitated to take the vaccine. On the other hand, people had a higher sense of understanding for antibodies, so antibody-based therapies were more widely-accepted.

The pandemic not only accelerated the improvement of existing strategies but also prompted the development of novel techniques. Technologies, such as high throughput surface plasmon resonance (SPR), high throughput biolayer interferometry (BLI), have garnered interest during the pandemic. In addition, high throughput dynamic light-scattering (DLS) and FLD have also improved a lot. One of the newer technologies was the artificial intelligence-based De Novo monoclonal antibody design, which increased the speed and complexity of antibody discovery platforms.

COVID-19 monoclonal antibody workflow

The first step to constructing the workflow is choosing the antigen to use for developing monoclonal antibodies. In the initial stage, immunization occurs by administering the antigen into an animal that develops an immune response. Then, the beta cells generated during the animal immune response are isolated, followed by fusion with a myeloma cell to generate the hybridoma.

According to Dr. Mitchell, the key to a successful initial stage is the optimization of the antigen. “In the case of COVID-19, antibodies are mainly raised against the spike protein, which is a trimer. The spike protein has a propensity of forming high molecular weight aggregates, which may not be great for immunization strategy”.

To add to that, glycosylation patterns of the spike protein highly vary across cell types, let alone different species.

That’s why one has to be very careful about antigen selection. Even a slight deviation of a single antigen glycan (e.g., in different variants) can significantly impact the success rate of the antibody.

Monoclonal Antibody Production, mAb

Challenges and bottlenecks

 

Immunization

One of the main challenges is the comprehension of the viral genome. Research teams usually had to synthesize and purify antigens and optimize their expression. However, to evaluate the success of expression and purification, they had to rely on the collaborative nature of scientists to publish the information from their own labs. Overall, the immunization of an animal and the generation of hybridoma alone could take up to eight weeks.

 

Single-cell isolation

Upon identifying the best quality antigen for the immunization strategy, the next challenge is to get a sufficient number of B cells for the single-cell isolation of hybridoma.

The traditional method to grow these hybridomas is a semi-solid medium that allows the single cell to form a colony. This used to be a slow process but has since gained momentum with robotic instruments that allow printing single cells into each well of a microwell plate, thereby improving both the throughput and efficiency.

It is important to note that advanced single-cell isolation tools also provide increased clonal outgrowth efficiency and monoclonality verification that the colony was generated from a single cell.

 

Large-scale monoclonality

For large-scale monoclonality, one needs to generate the recombinant form of a single-cell-isolated hybridoma because single-cell isolation is insufficient for clinically-relevant mAb generation. The approval for clinical trials would require the recombinant generation of the mAb and its formulation into a human antibody that allows for the appropriate immunologic response.

To form stable cell lines to generate mAbs at sufficient concentrations, you need to sequence and manipulate the gene into a human construct. CHO cell lines are used for the recombinant generation, with the aim of 8-20 g/L mAb production.

 

Cell Line Antibodies

Time and financial constraints

 

Time and cost are key factors to consider in mAb workflows

Although the generation of stable clones can be achieved in 12 days upon initial feeding, full monoclonal assurance could take up to six months with traditional cloning methods. More importantly, generating a fully-realized mAb structure can be expensive. The solution would be to form single-chain variable fragment antibodies or VHH nanobodies. These are the smallest antibody fragments possible exhibiting specific binding affinity for an antigen. Dr. Mitchell summarizes why this approach is so powerful:

“By converting mAbs into smaller nanobodies, we can produce them in E. coli in a much more cost-effective manner. That drives down the costs, making it a broadly applicable therapeutic as opposed to those only accessible in developed countries.”

According to Dr. Madasu, their stable structures make distribution into less-developed countries more effortless. “We need to think about other lesser developed countries without access to storage facilities. Some of these nanobodies are pretty stable and they could be stored at less stringent conditions.”

Clearly, antibody-to-nanobody conversion is a crucial step to distribute mAbs-based therapies across the globe at a lower cost. Especially in less-developed countries with insufficient storage facilities, nanobodies would still remain stable in extreme temperatures.

 

Ensuring monoclonality and accelerating COVID-19 mAb production with automation

 

Monoclonality assurance

Methods to ensure monoclonality at scale include automated technologies like single-cell printing or colony-picking. When picking an isolated colony from the HAT medium, the instrument takes images over a time-lapse from day zero after picking the colony. The eye-witness proof constitutes evidence of monoclonality. To assure high-performing clones labs can use cell-based or immune-based assays combined with image-based methods. This combined strategy ensures that you have monoclonality and that your clones are secreting a single variety of the antibody. As a final step in the process, it is also helpful to run epitope binding assays to determine if the epitope binding is uniform.

Ensuring Monoclonality and Accelerating COVID-19 mAb Production

 

The role of robotics in turnaround time

The ultimate way to decrease the development timeline is to implement high throughput robotics to interrogate the clones. In automated mAb workflows for COVID-19, automated purification has been of immense help to understand the behavior of the clones and the possibility of the monoclonal antibody making high molecular weight aggregates.

Utilizing robotics in a high throughput manner is always an advantage in bringing novel therapeutics to market, This method provides a better overview of the protein space or epitope space. Having a high number of clones maximizes your chances of obtaining mAbs that cover all the desired attributes instead of having a single mAb with partial coverage of the antigen.

With high-throughput workflows, one can narrow focus into a subset of mono-clones with the highest yield. You can then move forward with the highest-ranked subsets to run further assessments in animal studies and toxicology tests. You would also save time by eliminating subsets not suitable for large-scale purifications, which prevents monetary drain during the laboratory’s COVID-19 research journey.

 

Automation of mAb lab processes in the future

Many COVID-19 research laboratories have already implemented automated processes since they are able to generate data for thousands of clones a week. Comprehension of mAb therapeutic mechanisms is much more likely with automated synthesis, expression, purification, and biophysical characterization.

More importantly, automation paves the way for unbiased analysis methods and selection criteria. Objective analysis is necessary for diversifying the library of antibodies for a broad range of variants and mutations to avoid scaling up antibodies that only treat a narrow set of variants.

 

Future of SARS-CoV-2 research and the role of monoclonal antibodies

mAb-based therapeutics have been on the United States market since 1986 with the first mAb FDA approval of muromonab-CD3 (Orthoclone OKT3) development to reduce acute rejection in patients with organ transplants. (1) Current COVID-19 research increases the significance of monoclonal antibodies in diagnostics as well. In fact, monoclonal antibodies played a vital role in detecting SARS-CoV-2 variants.

Besides diagnostics, current mAbs help researchers determine necessary modifications and even inform the development of vaccine candidates. In investigating whether a reference mAb can neutralize a virus variant, researchers can decide whether to develop more efficient novel therapeutics.

While mRNA-based vaccines have been at the center of the battle against COVID-19, monoclonal antibodies have been behind the scenes of various applications, from protein-based vaccines to antibody-based therapeutics.

Dr. Madasu and Dr. Mitchell believe that going forward, monoclonal antibodies could be applied in particular to the unvaccinated population, including infants, patients with comorbidities (who do not respond well to vaccines), and people hesitating to get vaccinated. As mentioned earlier, the key is to produce cost-effective mAb-based therapeutics and make them as widely available as possible, by increasing efficiency in the discovery and production process.

 

Monoclonal antibody discovery for COVID-19 with Molecular Devices’ lab automation solutions

Lab Automation clone screening

Clone screening is one of the bottlenecks of monoclonal antibody discovery because you have to test and analyze thousands of cells with respect to the target antigen. Automated clone screening workflows can help overcome this burden by reducing hands-on time and unifying and standardizing data extracted from multiple processes.

Molecular Devices has constructed integrated workflow solutions for the essential steps. Automated cell-line development workflows aim to produce monoclonal cell lines producing consistent and sufficient levels of the target therapeutic protein. Automated molecular cloning workflow seeks to minimize errors and contamination during the isolation of DNA sequences, which are propagated as vectors into the species of your choice.

These workflows maximize the yield of target proteins while providing an opportunity to integrate other instruments for a fully automated workcell with robotics. . Overall, such workflows are cost-effective, time-saving, and easy to modify with changing research goals.

On our Lab Automation for High-Throughput Clone Screening page, you can learn more about cell line development workflows in greater depth. Don’t forget to check out our monoclonal antibody application page to view mAb production methods and the intricacies of every step involved.

  1. Wang, S. S., Yan, Y. S., & Ho, K. (2021). US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives. Antibody therapeutics, 4(4), 262–272. https://doi.org/10.1093/abt/tbab027
  • Share on LinkedIn
  • Share on Facebook
  • Share on Twitter
  • Share on Youtube

Recent posts

View All Posts
Spacer

3D organoids and automation of complex cell assays [Podcast]

As we enter the era of sophisticated drug discovery with gene therapy and…

Discover 3D organoids
Spacer

Celebrating the art of science: A D+I interview with Daniele Tortorella

At Molecular Devices, we cultivate a culture where associates around the…

Celebrate D+I
Spacer

Advanced technology for automated 3D biology workflows #SLASEurope2022

SLAS Europe 2022, hosted numerous sessions packed with the latest…

View SLAS EU activities
Spacer

[Podcast] Challenges of traditional cell line development and emerging technologies to help regulate monoclonality

Advancements in genetic engineering and synthetic biology have allowed…

Listen to CLD podcast
Spacer

Stem Cell Science and Regenerative Medicine – Technology and Methods Presented at ISSCR 2022

It was another great year at ISSCR 2022! Leaders from across the globe…

View ISSCR 2022 posters
Compare /

MICROPLATE READERS

  • SpectraMax i3x
  • SpectraMax iD3 / iD5
  • SpectraMax M Series
  • SoftMax Pro Software

CELLULAR IMAGING

  • ImageXpress Confocal HT.ai
  • ImageXpress Pico
  • IN Carta Image Analysis Software

CLONE SCREENING

  • ClonePix 2 Mammalian Colony Picker
  • QPix Microbial Colony Pickers

FLIPR SYSTEM

AXON PATCH-CLAMP

LAB AUTOMATION

GXP COMPLIANCE

  • News
  • Events
Feb 18, 2023

BPS (Biophysical Society)

Feb 25, 2023

SLAS (Society for Laboratory Automation and Screening)

Feb 27, 2023

BPI West (BioProcess International US West)

More Events

Jan 04, 2023

Molecular Devices and Advanced Solutions Life Sciences collaborate to develop 3D Biology Automation Technologies for Drug Discovery

Dec 06, 2022

Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce

Nov 02, 2022

Molecular Devices announces ValitaTiter IgG quantitation assay to fast track biologics sample testing

More News
Newsletter Loader
  • January 2023  
  • December 2022  
  • November 2022  

GLOBAL HEADQUARTERS

  • Address Icon

    Molecular Devices, LLC.
    3860 N First Street
    San Jose, CA 95134

  • Contact Us

    Phone: +1 800-635-5577

    Phone: +86-400-821-3787

    Phone: +44-118-944-8000

    Phone: +44-118-944-8000

    Phone: +82-2-3471-9531

    Teléfono: +44-118-944-8000

    Telefono: +44-118-944-8000

  • Office Timing

    Mon-Fri 8:00 am - 5:00 pm (PST)

    周一至周五,早上 9 点至下午 5 点 30 分

    Montag bis Freitag 8 h à 17 h (GMT)

    lundi à vendredi 8 h à 17 h (GMT)

    월~금, 오전 9시~ 오후 5시 (한국표준시)오후

    de lunes a viernes 8 h à 17 h (GMT)

    lunedi al venerdì 8 h à 17 h (GMT)

  • Product Sale

    Sales +1 877-589-2214

    售前咨询 : 400-821-3787 转 1

    Verkauf 00800 665 32860

    Ventes 00800 665 32860

    매상 82 2 3471 9531

    Ventas 00800 665 32860

    Saldi 00800 665 32860

  • Technical Support

    Support +1 800 635 5577

    售后咨询 : 400-821-3787 转 2

    Unterstützung +44-118-944-8000

    Support +44-118-944-8000

    지원하다 +82-2-3471-9531

    Apoyo +44-118-944-8000

    Supporto +44-118-944-8000

  • Knowledge Base

    Spectranet customer portal

Footer Nav

  • Terms & Conditions
  • Privacy Policy
  • Do Not Sell or Share My Data
  • Online Terms of Use
  • Trademarks
  • Support
  • Contact Us
  • Sitemap
  • Danaher Life Sciences
  • Careers

©2023 Molecular Devices, LLC. All rights reserved.

©2023 Molecular Devices, LLC. 美谷分子仪器(上海)有限公司保留所有权利。
All Rights Reserved 沪ICP备05056171号-1

barcode